Corbus Pharmaceuticals Welcomes Rachelle Jacques as New Board Chair
Norwood, Massachusetts — Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a prominent clinical-stage biopharmaceutical company dedicated to tackling oncology and obesity, has appointed Rachelle Jacques as Chair of its Board of Directors. This change became effective on May 15, marking a significant shift in leadership as she takes the reins from the founding Chair, Alan Holmer, who will continue to serve on the Board.
Yuval Cohen, Ph.D., the Chief Executive Officer of Corbus, expressed gratitude towards Alan Holmer for his over ten years of dedicated leadership. "Rachelle is a seasoned biopharmaceutical executive, and her innovative and strategic thinking has been invaluable to us as a Board member. We anticipate her vision and leadership as we embark on an exciting new chapter, with pivotal clinical readouts from our pipeline expected soon," he stated.
Rachelle Jacques: Experience and Vision
Rachelle Jacques shared her enthusiasm about stepping into the Chair role at a critical time for Corbus. "I feel privileged to take on this responsibility as we push our diverse pipeline towards significant milestones this year," she remarked. Jacques highlighted the company’s targeted oncology programs, CRB-701 and CRB-601, which aim to combat aggressive cancers. Additionally, she noted their obesity program, designed to address a pressing public health challenge, as a driving force for her motivation.
Reflecting on his tenure, Alan Holmer remarked, "Serving as Chair has been both an honor and privilege. We are clearly on a positive and exciting trajectory. Rachelle's extensive background in both big pharma and biotech will be crucial as we navigate this transition smoothly together." Jacques’ years of service on Corbus' Board and her contributions to various committees have led to this significant advancement in her career.
Jacques’ Background and Achievements
With over 25 years of experience in leadership, Rachelle Jacques has a proven track record of driving transformative therapies through various roles, including CEO and other high-ranking executive positions. She has been instrumental in advancing key initiatives at Corbus Pharmaceuticals and has previously served on the board of directors of uniQure N.V. (Nasdaq: QURE), accelerating gene therapies for genetic diseases. Her leadership journey included being the CEO of Akari Therapeutics Plc (Nasdaq: AKTX), where she developed treatments for autoimmune and inflammatory diseases.
Jacques has also held notable roles such as senior vice president at Alexion Pharmaceuticals, where she directed global commercialization strategies across multiple therapeutic areas. Her early career featured positions at Baxter, encompassing business operations and finance, and she has extensive international experience from her time at Dow Corning, managing operations across several continents.
Corbus’ Commitment to Innovation
Corbus Pharmaceuticals is committed to innovating solutions to tackle serious health challenges. The company’s therapeutic pipeline includes CRB-701, an advanced antibody-drug conjugate targeting cancer cells; CRB-601, an anti-integrin monoclonal antibody aimed at inhibiting TGF? activation; and CRB-913, which acts as a CB1 receptor inverse agonist designed for obesity treatment. This ambitious pipeline reflects the company's resolve in addressing critical health care issues.
As Corbus progresses, its headquarters located in Norwood remains the hub for navigating these advancements. The company is dedicated to exploring and developing scientifically-backed therapies that not only meet the immediate needs of patients but also pave the way for future innovations.
Through a combination of pioneering research, strategic leadership, and a clear vision for the future, Corbus Pharmaceuticals is poised to create meaningful change in the biopharmaceutical landscape.
Frequently Asked Questions
What does Rachelle Jacques’ appointment as Board Chair signify for Corbus?
Her appointment represents a commitment to strong leadership and strategic direction as the company advances its innovative pipeline of treatments.
How long has Rachelle Jacques been with Corbus Pharmaceuticals?
Rachelle Jacques has been a member of the Corbus Pharmaceuticals Board for over six years before becoming Chair.
What are the primary goals of Corbus Pharmaceuticals?
Corbus aims to develop therapies that address serious health conditions, particularly in oncology and obesity, through innovative scientific approaches.
What role did Alan Holmer play in Corbus Pharmaceuticals?
Alan Holmer served as the founding Chair of the Board and has provided leadership over the past ten years, continuing to support the company as a Board member.
Where is Corbus Pharmaceuticals headquartered?
The company is headquartered in Norwood, Massachusetts, and focuses on developing advanced therapeutic solutions.
